Bosentan for Treatment of Hepatopulmonary Syndrome in Patients With Liver Cirrhosis

Model scores of the 29,894 trials active now.

Model score 20% for any early termination, 6% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 21% of the time (143 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: placebodouble blindcontrolledrandomized doubleuse of
  Phrases that lowered it: patientstransplantationaccordingcontraceptionadequate
• Sponsor's past termination rate: 10.4% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Has a data monitoring committee: not given (lowers risk) · Design
• Drug's FAERS reports with a death: 52.9% (raises risk) · Drug's FDA history
• Blinding: quadruple (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Drug's FAERS reports marked serious: 95.5% (raises risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 76 (lowers risk) · Sponsor's track record
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Sponsor's past trials: 125 (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Number of arms: 2 (raises risk) · Design
• Disease area, respiratory: Yes (raises risk) · Disease area
• Collaborators: 0 (raises risk) · Design
• Responsible party: principal investigator (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Letrozole in Patients With Hepatopulmonary Syndrome NCT04577001 · started 2021 · scored riskier than 94% of active trials terminated
• Sorafenib for Hepatopulmonary Syndrome NCT02021929 · started 2014 · scored riskier than 64% of active trials terminated
• Randomized Controlled Trial to Assess the Effects of Sapropterin on Hepatic and Systemic Hemodynamics in Patients With Liver Cirrhosis and Portal Hypertension NCT01456286 · started 2011 · scored riskier than 66% of active trials completed
• Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial NCT01224210 · started 2010 · scored riskier than 79% of active trials completed
• Efficacy of the Combination of Simvastatin Plus Rifaximin in Patients With Decompensated Cirrhosis to Prevent ACLF Development NCT03780673 · started 2019 · scored riskier than 68% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.